Ironwood Pharmaceuticals: Pioneering GI Peptide Therapeutics with Linzess as a Blockbuster and Expanding Pipeline

In recent years, with the successive market launches of “blockbuster” drugs such as liraglutide and semaglutide, the peptide sector has returned to the public spotlight.

In 2021, Linzess® (linaclotide) achieved net sales exceeding $1 billion in the United States, emerging as a new “blockbuster” drug in the peptide therapeutics sector.

This drug was approved by China’s National Medical Products Administration (NMPA) as early as 2019 for the treatment of adult patients with irritable bowel syndrome with constipation (IBS-C), filling a therapeutic gap in the management of adult IBS-C in China.

Linaclotide, the world’s first guanylate cyclase-C (GC-C) agonist developed by Ironwood, has long been a leader in the branded prescription market for constipation treatment, representing Ironwood’s pinnacle achievement in the gastrointestinal (GI) field.

Irowood has established a robust partnership network to support the global commercialization of linaclotide in the United States, Europe, Japan, China, and other regions, while actively advancing its next-generation pipeline of innovative gastrointestinal (GI) therapies, with the aim of becoming a leading GI healthcare company in the United States.

With over 30 years of development history and extensive industry experience, Ironwood traces its origins to Microbia, which was founded in 1988 by the Whitehead Institute at the Massachusetts Institute of Technology (MIT). After years of growth, Ironwood successfully listed on the NASDAQ in February 2010 under the ticker symbol IRWD.

Ironwood Has Attracted Significant Investor Interest. According to incomplete statistics, since its establishment, Ironwood has completed more than 10 rounds of financing, with a total amount exceeding $600 million.

Data source: Crunchbase

Beyond its long history and strong financing capabilities, Ironwoo is best known for its blockbuster product, linaclotide.

Linaclotide is the world’s first guanylate cyclase-C (GC-C) agonist. It activates GC-C receptors to increase intracellular cyclic guanosine monophosphate (cGMP) levels, thereby promoting intestinal fluid secretion and improving bowel movements. Additionally, it elevates extracellular cGMP concentrations, reduces nociceptive nerve activity, and alleviates abdominal pain. Linaclotide thus exhibits a dual mechanism of action: enhancing intestinal fluid secretion/transport and reducing visceral hypersensitivity.

,

Linaclotide was approved by the U.S. FDA in August 2012 for the treatment of chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C) in adults. In 2017, the FDA approved 72 mcg LINZESS (linaclotide) for the treatment of CIC. To date, the U.S. FDA has approved three dosages of linaclotide: 290 mcg for the treatment of adult patients with IBS-C, and 145 mcg and 72 mcg for the treatment of adult patients with CIC.

In addition to the United States, linaclotide is marketed in over 40 countries, including Japan, China, and Canada, with a global sales network.

In January 2019, linaclotide was approved by China’s National Medical Products Administration (NMPA) for the treatment of adult patients with irritable bowel syndrome with constipation (IBS-C), and it was officially launched in China in November of that year, filling a therapeutic gap for adult IBS-C in the country. Phase III clinical trials in China confirmed that, compared with placebo, linaclotide significantly alleviated IBS-C–related symptoms, with the proportion of responders achieving symptom relief more than double that of the placebo group (31.7% vs. 15.4%). Efficacy was evident as early as the first week of treatment, and symptoms continued to improve throughout the treatment period. Furthermore, because linaclotide acts locally in the intestine with negligible systemic absorption, it has a favorable safety profile. Studies have shown that the most common adverse reactions to linaclotide are mild to moderate diarrhea, with no clinically significant sequelae observed.

To further promote the global application of linaclotide, Ironwood has established partnerships with numerous major pharmaceutical companies. In North America and Europe, Ironwood collaborates with AbbVie to market linaclotide (branded as Linzess in the United States and Constella in Europe); in Japan, Astellas is responsible for the development and commercialization of linaclotide; AstraZeneca serves as Ironwood’s partner in the Chinese market.

Overall, however, the sales market for linaclotide remains dominated by the United States. In 2021, net sales of linaclotide (Linzess) in the U.S. surpassed the $1 billion mark, establishing it as a “blockbuster” drug among its peers and generating substantial revenue for Ironwood. According to IQVIA data, total prescription demand for Linzess reached 159 million capsules in 2021.

Linzess: U.S. Net Sales and Total Annual Prescription Demand (Source: Irowood Annual Report)

While building its global sales network, Ironwood is also actively recruiting talent aligned with the company’s future commercialization strategy.

In June 2021, Thomas McCourt officially became the new Chief Executive Officer and a member of the Board of Directors at Ironwood. Mr. McCourt brings extensive experience in marketing and business development. He formally joined the company in 2009, having served as Senior Vice President of Marketing, Chief Business Officer, and Interim Chief Executive Officer. Prior to joining Ironwood, he led the U.S. brand team for denosumab at Amgen, oversaw the promotion of ZELNORM™ at Novartis AG, and was a founding team member at Astra Merck, where he served as Brand Manager for PRILOSEC® and NEXIUM®.

Currently, Linzess is indicated only for adult patients aged 18 and older; however, a substantial number of children suffer from functional constipation (FC). To meet the clinical needs of a broader patient population, Ironwood Pharmaceuticals is actively expanding the approved age range for Linzess. In September 2022, Ironwood announced that its Phase III clinical trial of Linzess in pediatric patients aged 6 to 17 years with functional constipation met both primary and secondary endpoints. As the U.S. Food and Drug Administration (FDA) has not yet approved any prescription therapy for functional constipation (FC) in children, Linzess is poised to become the first such treatment.

Irowood is committed to redefining the standard of care for patients with gastrointestinal (GI) disorders. To strengthen its innovation capabilities in the GI field, Irowood is actively expanding its indications beyond chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C), resulting in a diverse drug development pipeline. Among these, IW-3300 and CNP-104 are particularly noteworthy candidates.

Product Introduction (Image Source: Irowood Official Website)

IW-3300 is a guanylate cyclase-C agonist under investigation for the potential treatment of visceral pain disorders, such as interstitial cystitis/bladder pain syndrome (IC/BPS) and endometriosis, which affect millions of patients in the United States. Ironwood has successfully completed Phase I studies and expects to initiate a Phase II proof-of-concept study in patients with IC/BPS by the end of 2022.

CNP-104 is a tolerogenic immune-modulating nanoparticle for the treatment of primary biliary cholangitis (PBC), a rare autoimmune disease targeting the liver. Ironwood has entered into a collaboration and license option agreement with the biopharmaceutical company COUR, securing exclusive rights to research, develop, manufacture, and commercialize products containing CNP-104 in the United States. The FDA has granted Fast Track designation to CNP-104, and Ironwood expects to release data in 2023. If development is successful, CNP-104 has the potential to become the first approved disease-modifying therapy for PBC.

Irowood has long been dedicated to the gastrointestinal (GI) sector, with total annual revenue reaching $400.4 million in 2021, establishing itself as a significant player in the GI field. Leveraging the sustained strong market demand for its peptide drug linaclotide, Irowood plans to achieve single-digit growth in net sales of linaclotide in the United States in 2022, while maintaining total revenue between $420 million and $430 million.